Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.
American Cancer Society. Cancer Facts & Figures 2017. 2017; https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html.
Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91(18):1541–8.
Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and bowel project P-1 study. J Natl Cancer Inst. 2005;97(22):1652–62.
Cuzick J, Sestak I, Cawthorn S, et al. Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol. 2015;16(1):67–75.
Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet. 2014;383(9922):1041–8.
Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364(25):2381–91.
Nelson HD, Smith ME, Griffin JC, Fu R. Use of medications to reduce risk for primary breast cancer: a systematic review for the U.S. preventive services task force. Ann Intern Med. 2013;158(8):604–14.
Wise J. NICE recommends preventive drugs for breast cancer. BMJ. 2013;346:f4116.
Bevers TB. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer Risk Reduction. 2012; https://www.nccn.org/professionals/physician_gls/default.aspx#breast.
Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27(19):3235–58.
Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28(18):3090–5.
Smith SG, Sestak I, Forster A, et al. Factors affecting uptake and adherence to breast cancer chemoprevention: a systematic review and meta-analysis. Ann Oncol. 2016;27(4):575–90.
Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011;127(3):681–8.
Owens WL, Gallagher TJ, Kincheloe MJ, Ruetten VL. Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract. 2011;7(2):85–8.
Kaplan CP, Livaudais-Toman J, Tice JA, et al. A randomized, controlled trial to increase discussion of breast cancer in primary care. Cancer Epidemiol Biomark Prev. 2014;23(7):1245–53.
Legare F, Robitaille H, Gane C, Hebert J, Labrecque M, Rousseau F. Improving decision making about genetic testing in the clinic: an overview of effective knowledge translation interventions. PLoS One. 2016;11(3):e0150123.
Holmberg C, Bandos H, Fagerlin A, et al. NRG oncology/National Surgical Adjuvant Breast and bowel project decision-making Project-1 results: decision making in breast Cancer risk reduction. Cancer Prev Res (Phila). 2017;10(11):625–34.
Korfage IJ, Fuhrel-Forbis A, Ubel PA, et al. Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention. Breast Cancer Res. 2013;15(5):R74.
Meiser B, Wong WKT, Peate M, Julian-Reynier C, Kirk J, Mitchell G. Motivators and barriers of tamoxifen use as risk-reducing medication amongst women at increased breast cancer risk: a systematic literature review. Hered Cancer Clin Pract. 2017;15:14.
Coe AM, Ueng W, Vargas JM, et al. Usability testing of a web-based decision aid for breast Cancer risk assessment among multi-ethnic women. AMIA Annu Symp Proc. 2016;2016:411–20.
McGuinness J, Ueng W, Trivedi MS, et al. Factors associated with false positive results on screening mammography in a population of predominantly Hispanic women (in press). Cancer Epidemiol Biomark Prev. 2017.
Kukafka R, Yi H, Xiao T, et al. Why breast Cancer risk by the numbers is not enough: evaluation of a decision aid in multi-ethnic, low-numerate women. J Med Internet Res. 2015;17(7):e165.
A I. The theory of planned behavior. Organ Behav Hum Decis Process. 1991.
Yi H, Xiao T, Thomas PS, et al. Barriers and facilitators to patient-provider communication when discussing breast Cancer risk to aid in the development of decision support tools. AMIA Annu Symp Proc. 2015;2015:1352–60.
Chew LD, Bradley KA, Boyko EJ. Brief questions to identify patients with inadequate health literacy. Fam Med. 2004;36(8):588–94.
Lipkus IM, Samsa G, Rimer BK. General performance on a numeracy scale among highly educated samples. Med Decis Mak. 2001;21(1):37–44.
Mandelblatt J, Kaufman E, Sheppard VB, et al. Breast cancer prevention in community clinics: will low-income Latina patients participate in clinical trials? Prev Med. 2005;40(6):611–8.
Williams GC, Rodin GC, Ryan RM, Grolnick WS, Deci EL. Autonomous regulation and long-term medication adherence in adult outpatients. Health Psychol. 1998;17(3):269–76.
Lipkus IM, Kuchibhatla M, McBride CM, et al. Relationships among breast cancer perceived absolute risk, comparative risk, and worries. Cancer Epidemiol Biomarkers Prev. 2000;9(9):973–5.
Armstrong K, Micco E, Carney A, Stopfer J, Putt M. Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer. JAMA. 2005;293(14):1729–36.
Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med. 1991;114(8):657–61.
O'Connor AM. Validation of a decisional conflict scale. Med Decis Mak. 1995;15(1):25–30.
Kreuter MW, Strecher VJ. Changing inaccurate perceptions of health risk: results from a randomized trial. Health Psychol. 1995;14(1):56–63.
Daly MB, Lerman CL, Ross E, Schwartz MD, Sands CB, Masny A. Gail model breast cancer risk components are poor predictors of risk perception and screening behavior. Breast Cancer Res Treat. 1996;41(1):59–70.
Stalmeier PF, Unic IJ, Verhoef LC, Van Daal WA. Evaluation of a shared decision making program for women suspected to have a genetic predisposition to breast cancer: preliminary results. Med Decis Mak. 1999;19(3):230–41.
Graves KD, Huerta E, Cullen J, et al. Perceived risk of breast cancer among Latinas attending community clinics: risk comprehension and relationship with mammography adherence. Cancer Causes Control. 2008;19(10):1373–82.
LeBlanc A, Kenny DA, O'Connor AM, Legare F. Decisional conflict in patients and their physicians: a dyadic approach to shared decision making. Med Decis Mak. 2009;29(1):61–8.
Izadi S, Pachur T, Wheeler C, McGuire J, Waters EA. Spontaneous mental associations with the words "side effect": implications for informed and shared decision making. Patient Educ Couns. 2017;100(10):1928–33.
Hoerger M, Scherer LD, Fagerlin A. Affective forecasting and medication decision making in breast-cancer prevention. Health Psychol. 2016;35(6):594–603.
Waters EA, Weinstein ND, Colditz GA, Emmons K. Explanations for side effect aversion in preventive medical treatment decisions. Health Psychol. 2009;28(2):201–9.
Waters EA, Weinstein ND, Colditz GA, Emmons KM. Reducing aversion to side effects in preventive medical treatment decisions. J Exp Psychol Appl. 2007;13(1):11–21.
Bober SL, Hoke LA, Duda RB, Regan MM, Tung NM. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22(24):4951–7.
Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Familial Cancer. 2005;4(2):97–103.
Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006;21(7):779–85.
Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3(3):242–7.
Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8(7):580–5.
Stacey D, O'Connor AM, DeGrasse C, Verma S. Development and evaluation of a breast cancer prevention decision aid for higher-risk women. Health Expect. 2003;6(1):3–18.
Melnikow J, Paterniti D, Azari R, et al. Preferences of women evaluating risks of tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103(10):1996–2005.
Juraskova I, Bonner C. Decision aids for breast cancer chemoprevention. Breast Cancer Res. 2013;15(5):106.
Anderson CJ. The psychology of doing nothing: forms of decision avoidance result from reason and emotion. Psychol Bull. 2003;129(1):139–67.
Luce MF. Choosing to avoid: coping with negatively emotion-laden consumer decisions. J Consum Res. 1998;24:409–33.
Martinez KA, Fagerlin A, Witteman HO, Holmberg C, Hawley ST. What matters to women when making decisions about breast Cancer chemoprevention? Patient. 2016;9(2):149–59.
Misra-Hebert AD, Kattan MW. Comment on: decisional conflict, regret, and the burden of rational decision making. Med Decis Mak. 2017;37(4):E360–1.
Vickers AJ. Response to "comment on: decisional conflict, regret, and the burden of rational decision making". Med Decis Mak. 2017;37(4):E362.
Vickers AJ. Decisional conflict, regret, and the burden of rational decision making. Med Decis Mak. 2017;37(1):3–5.
O'Connor AM, Fiset V, DeGrasse C, et al. Decision aids for patients considering options affecting cancer outcomes: evidence of efficacy and policy implications. J Natl Cancer Inst Monogr. 1999;(25):67–80.
Holmberg C, Waters EA, Whitehouse K, Daly M, McCaskill-Stevens W. My lived experiences are more important than your probabilities: the role of individualized risk estimates for decision making about participation in the study of tamoxifen and Raloxifene (STAR). Med Decis Mak. 2015;35(8):1010–22.
Reyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Mak. 2008;28(6):850–65.
Finucane ML, Alhakami A, Slovic P, J SM. The affect heuristic in judgments of risks and benefits. J Behav Decis Mak. 2000;13(1):1–17.
Padamsee TJ, Muraveva A, Yee LD, Wills CE, Paskett ED. Experiencing the cancer of a loved one influences decision-making for breast cancer prevention. J Health Psychol. 2017. https://doi.org/10.1177/1359105317746480.